==================================================================================

FORM 10-KSB

SECURITIES AND EXCHANGE COMMISSIONWashington, D. C. 20549

**[ x ]  **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** **For the fiscal year ended - December 31, 2003** **OR**[   ]**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  SECURITIES EXCHANGE ACT OF 1934** **For the transition period from**Commission file number 0-30414

ALR TECHNOLOGIES, INC.(Exact name of registrant as specified in its charter)

**NEVADA(State or other jurisdiction of incorporation or organization)**88-0225807(Employer Identification No.)
**101 North Chestnut Street Suite 307Winston-Salem, North Carolina 27101(Address of principal executive offices, including zip code.)
**(336) 722-2254(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: **None**

Securities registered pursuant to Section 12(g) of the Act: **Common Stock**
Check whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES  [ x ]    NO [   ] 

Check if no disclosure of delinquent filers pursuant to Item 405 of Regulation S-B is contained herein, and no disclosure will be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. [   ]

==================================================================================

 

 

State Issuer's revenues for its most recent fiscal year**.  December 31, 2003 - $175,820**
The aggregate market value of the voting stock held by non-affiliates on **April 8, 2004 was $1,335,491.**  There are approximately **19,078,446** shares of common voting stock of the Registrant held by non-affiliates. 

Issuers involved in Bankruptcy Proceedings during the past Five Years. Not Applicable.

State the number of shares outstanding of each of the Issuer's classes of common equity, as of the latest practicable date: **April 9, 2004 - 21,078,446**shares of Common Stock

Transitional Small Business Issuer Format     YES [   ]     NO [ x ]
**Forward Looking Statements**
Except for the description of historical facts contained herein, this Form 10-KSB contains certain forward-looking statements concerning future applications of the technologies of the Company and the Company's proposed services and future prospects, that involve risks and uncertainties, including the possibility that the Company will: (i) be unable to commercialize services based on its technology, (ii) ever achieve profitable operations, or (iii) not receive additional financing as required to support future operations, as detailed herein and under "Item 6, Management's Discussion and Analysis or Plan of Operations" and from time to time in the Company's future filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements.

 

 

 

 

 

-2-
**PART I

ITEM 1.       BUSINESS.****Background**
ALR TECHNOLOGIES, INC. (the "Company") was incorporated under the laws of the State of Nevada on March 24, 1987 as Mo Betta Corp.  On December 28, 1998, the Company changed its name from Mo Betta Corp. to ALR Technologies Inc.  

Prior to April 1998, the Company was inactive.  In April 1998, the Company changed its business purpose to marketing and assembling a pharmaceutical compliance device which was owned by A Little Reminder (ALR) Inc. ("ALR"). 

On October 21, 1998, the Company entered into an agreement with ALR whereby the Company would have the non-exclusive right to distribute certain products of ALR described below.  

In April 1999, the Company acquired 99.9% (36,533,130) of the issued and outstanding Class A shares of common stock of ALR in exchange for 36,533,130 shares of the Company's common stock thereby making ALR a subsidiary corporation of the Company.  ALR also had outstanding 124,695 shares of Class B common stock, none of which was owned by the Company.

ALR was incorporated pursuant to the Company Act of British Columbia on May 24, 1996.  ALR continued its jurisdiction under the laws of Canada on September 23, 1996 and to the state of Wyoming on July 31, 1998. 

ALR owned one subsidiary corporation, Timely Devices, Inc. ("TDI").  TDI was founded in Edmonton, Alberta, Canada on July 27, 1994.  ALR owns all of the total outstanding shares of TDI.  TDI had only one class of common stock outstanding.  On July 31, 2000, the Company sold all of its shares of ALR. As a result of this sale, the Company is no longer using the technology that was used by its previously owned subsidiaries and does not have any assembly capability.  The Company now does its own marketing and has designed products based on new technology.  The manufacturing and assembling of these products has been contracted out.

In December 1998, the common shares of the Company began trading on the Bulletin Board operated by the National Association of Securities Dealers Inc. under the symbol "MBET."  Subsequently the symbol was changed to "ALRT." 
**Products**
The Company has developed a line of medication compliance devices that will assist people with taking their medication on time ("Reminders").  The primary market is the human medication market but a secondary markets exists for vison care and contact lens replacement reminders, reminders for vitamin, nutrition and weight management programs and reminders for medications for companion animals.

 

 

-3-
**Basic Model - ALRT Med Reminder**
The Company introduced its Basic Human Reminder, the ALRT Med Reminder, in the third quarter of 2002 and inventory was available to fill orders in October of 2002. The reminder is compact, approximately 2 1/4" x 1 3/4" x 1/2".  It is programmed by its user to remind up to 6 events daily. The programming is accomplished simply by depressing the single programming button on the face of the unit at the times the user would like a reminder. The same button is used to de-program and reprogram the unit. The reminder cue consists of both audio tone and visual cues. Features include: loop for clip or ring, speaker, LED, programming button, lockout switch, early activation feature, carrying case and replaceable batteries.
**ALRT Med Reminder PC100**
The Company introduced its ALRT Med Reminder PC100 in December 2002 with inventory that became available to fill orders in January of 2003. This model offers the capability of  programming the unit for all desired reminder events at one time from a PC computer by either the end user or by a healthcare professional and sent home with the patient.  The product includes a programming cable and software on CD ROM. The software can also be downloaded from the ALRT website. The unit reminds the user up to eight different programmed times per day. Features include: loop for clip or ring, speaker, LED, programming button, early activation feature, carrying case, and replaceable batteries.

Since the introduction of the ALRT Med Reminder PC100, the Company has upgraded the programming software and is currently offering Version 1.5 for download from the Company's website.  Amongst other new features, the latest software allows a user to choose English, French or Spanish as programming language.
**Once-A-Day Med Reminder**
This model has been completed and available for custom orders.  It is a once-a-day, very easy to use reminder for people who need only a single daily reminder. The unit is programmed initially by pulling the tab at the time user would like daily reminder. Deprogramming and reprogramming are accomplished by using the single button on the face of the unit. The reminder cue consists of both audio tone and visual cues. Features include: loop for clip or ring, speaker, LED, button, lockout switch, easy programming pull-tab and replaceable batteries.
**Other Developments**
Other programming modes are also available in the basic model.  All the modes are based on the ease of use principal of the Once-A-Day model.  Modes available include 48-Hour Reminder, Weekly Reminder, 14-Day Reminder, Monthly Reminder.  The Company is completing development to include an LCD for this model.  The display would alternate between days or hours to alarm and the actual time.  These models will be available for custom orders in the first half of 2004.

 

 

-4-
**Desktop Model**
All the modes available in the Basic Model are also available in a new Desktop Model which also features an LCD.  All these models will also be available for custom orders in the first half of 2004.
**Pillbox Model**
This model is expected to be available in the second half of 2004.  It features a reminder with a detachable pillbox.  The reminder with the pillbox attached will be 3 1/2" x 2 1/2" x 5/8".  This model will be available in both the single button programming 6 entries per day and the PC computer programmable PC100. Features include: speaker, LED, button, lock-out switch, detachable pill box, replaceable batteries, early activation feature.  The PC100 model also will include programming software on a CD ROM and a programming cable. 
**ALRT Med Reminder PC500**
Completion of development process and commercial introduction is expected during the last half of 2004.  This model is PC programmable and contains a LCD display that provides the added feature of not only reminding a person it is time to take medication but also displaying the actions/medications to take at the time of each reminder event.  Additional memory will allow the Reminder to store the list medications used by the patient, an emergency contact list and compliance profile of the patient for up to 12 months.
**ALRT Interactive Reminder System (AIRS)**
This system is currently in development and pilot versions are planned in 4th quarter 2004.  In addition to the reminder capability in the PC 500, this system will provide the additional capability that allows for the remote monitoring of reminder acknowledgements enabling a treatment center or other caregiver to intervene if it is deemed that the patient may not be taking their medications as prescribed.  AIRS will also allow a treatment center to remotely change a patient's reminder timing and/or the actions/doses/medications to take at the time of each reminder event.  This interactive system was designed and developed in response to the needs of patients with special and critical needs, such as organ transplant recipients, cancer patients, severe diabetics, HIV patients and more.
**Pet RemindersTM**
A new 30-Day Pet Reminder with replaceable batteries, designed for use in conjunction with monthly companion animal medication, has been available since December 2003.  

 

 

-5-

Another model which reminds the user once every 30 days at the day and time programmed has been developed and manufacturing timing will be based on orders. Liquid Crystal Display (LCD) provides a 30-day countdown until the next reminder event. Unit is programmed initially by pulling the tab at the day and time user would like reminder. Deprogramming and reprogramming is accomplished by using the single button on the face of the unit. The reminder cue consists of both audio tone and visual cues. Features include magnetic back, speaker, LCD, button, lockout switch and easy programming pull-tab.  

A daily Pet Reminder which is programmed by its user to remind up to 6 events daily has been developed. The programming is accomplished simply by depressing the single programming button on the face of the unit at the times the user would like a reminder. The same button is used to de-program and reprogram the unit. The reminder cue consists of both audio tone and visual cues. Features include: speaker, LED, button, lockout switch.  This model is also being offered to pharmaceutical manufacturers.
**Benefits of Medication Reminders**
The Company believes that medication reminders benefit patients by alerting them to take medication at a prescribed time thereby improving compliance which can enhance the likelihood of people receiving the intended benefits of medications.  If people do not receive the intended benefit of medication they may not get well and it could lead to further complications. This not only compromises the health effect on patients but also can lead to substantially increased cost of providing healthcare.  Industry data indicates 50% or more of people on medications do not take them as prescribed, and that this noncompliance contributes to 10% of hospitalizations and billions of dollars annually in excessive and preventable healthcare costs.
**Business Development and Marketing Strategy**
Management is focusing the majority of its efforts on introducing and marketing its line of medication reminders for the human healthcare market.  ALRT Med Reminders are being marketed and sold directly to disease management companies, health insurance providers, pharmaceutical manufacturers, retail pharmacy chains,  contract research organizations, and through distribution companies for resale to independent pharmacies.  The Company is first targeting customers located in United States because of the large market potential but will also be establishing selling operations/agreements for sales and distribution in Canada, Europe, Australia and selected countries in Asia and South America.
**Selling Activities**
The company has contracts with sales organizations that have long-standing relationships with most of the leading pharmacy retail chains (including supermarkets and mass merchandisers) in the US and expects to sign agreements with additional sales companies in 2004.  The company will also support retail product sales with promotion activities as working capital allows. Contracts with companies that will provide selling support to medical institutions and large medical practices are expected to be completed in first half of 2004---an agreement with one company was completed in 2002 and two

 

 

-6-

additional agreements were completed in 2003. Company management will provide much of the selling activity to contract research organizations, pharmaceutical manufacturers and health maintenance organizations.  The company will also utilize advertising/promotion and publicity activities to pharmaceutical manufacturers, contract research organizations, independent pharmacies and consumers.
**Pet Market Activities**
Since 2002 the Company has focused resources on developing the human medication reminder product line and as a result, they placed no resources or effort on selling the pet market products.  The Company continues to believe there is substantial need and market potential for their pet reminder products and will place effort and resources on this market as cash flow allows resource allocation for this market.  The Company continues to receive inquiries about their pet reminder products and will focus on selling to pet store retailers and grocery retailers as well as to pet medication pharmaceutical companies.
**Patents and Trademarks**
The Company has applied for the following trademarks and design patents:

 
1. 
Trademark Application Serial Number 76/114997 Filed Aug. 21, 2000.  Intent to Use Application covering the mark ALRT used with a programmable electronic reminder for administration of Scheduled Medications.
 
2. 
Trademark Application Serial Number 76/114998 Filed Aug. 21, 2000.  Intent to Use Application covering the mark Pet Reminder used with a programmable electronic reminder for administration of Scheduled Veterinary Medications or Treatments.
 
3. 
Trademark Application Serial Number 76/148174 Filed Oct. 16, 2000.  Intent to Use Application covering the Animal Paw Design.
 
4. 
Trademark Application Serial Number 76/148171 Filed Oct. 16, 2000.  Intent to Use Application covering the Dogbone Design.
 
5. 
Trademark Application Serial Number 76/148170 Filed Oct. 16, 2000.  Intent to Use Application covering the Heart Design.
 
6. 
Design Patent Application Serial Number 29/131,217 Filed Oct. 16, 2000 for the ornamental design of a medication alert device in the shape of a stylized paw.
 
7. 
Design Patent Application Serial Number 29/131,170 Filed Oct. 16, 2000 for the ornamental design of a medication alert device in the shape of a dogbone.
 
8. 
Design Patent Application Serial Number 29/131,203 Filed Oct. 16, 2000 for the ornamental design of a medication alert device in the shape of a heart.
 
9. 
Provisional Patent Application Serial Number 60/388,264 Filed June 13, 2002 for the portable programmable medical alert device.
While the Company believes the foregoing events will occur as described above, there is no assurance that the timetable for the programming methods will be available as indicated.

 

 

-7-

The Company spent $173,828 for the year ended December 31, 2003 on product research and development as compared with $165,973 for the year ended December 31, 2002.  The Company plans to spend $150,000 on product research and development in the next fiscal year.
**Competition**
The Company competes with other corporations that produce medication compliance devices, some of whom have greater financial, marketing and other resources than the Company. 

The Company believes that the approximate number of competitors is six, but the Company does not have any information to estimate its share of the market.  The principal methods employed by competitors are information pamphlets, compliance packaging, as well as other forms of devices.  The devices include clocks, labels, organization systems and pagers.

There are several companies that have established web sites to sell medication compliance devices direct to end-users.
**Employees**
The Company presently employs five persons,  three of whom are officers of the Company.  The Company intends to hire additional employees on an as-needed basis.
**Risk Factors**Limited History of Operations and Reliance on Expertise of Certain Persons.
  The Company has a limited history of operations. The management of the Company and the growth of the Company's business relies on certain key individuals who may not be easily replaced if they should leave the Company.  
Market Acceptance.
  The Company's success and growth will depend upon the Company's ability to market its existing products.  The Company's success may depend in part upon the market's acceptance of, and the Company's ability to deliver and support its products. See "Business - Products."
Liquidity; Need for Additional Financing; Going Concern Comments.
  The Company believes that it will need additional cash during the next twelve months to finance operations and to repay $5,723,500 of debt due on demand and $66,500 of debt due in fiscal 2004.  Assuming the Company has no sales and is unable to sell any securities or arrange additional debt financing, the Company believes that it can continue operations through to the end of the second quarter of fiscal 2004.  If the Company is unable to generate a positive cash flow before its cash is depleted, it will be required to curtail operations substantially, and seek additional capital.  There is no assurance that the Company will be able to obtain additional capital if required, if capital is available, or to obtain it on terms favorable to the Company. The Auditors' report on the Company's financial statements for the year ended December 31, 2003 includes an explanatory paragraph that states that the Company has suffered recurring losses, negative cash flow from operations and has a net capital deficiency at December 31, 2003, factors which raise substantial doubt about the Company's ability to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
 
-8-
Technology Risk.
  The Company and its competitors utilize different applications of known technology.  Should a competitor develop a technological breakthrough that cannot be adapted to the Company's systems or develop a more effective application of existing technology, the Company's products would be at risk of becoming obsolete.
Competition.
 Some of the Company's competitors may have substantially greater financial, technical and marketing resources than the Company.  In addition, the Company's products compete indirectly with numerous other products. The Company's products compete with clocks, pagers, labels and information systems, all of which, indirectly, remind a person to take his medication.  As the markets for the Company's products expand, the Company expects that additional competition will emerge and that existing competitors may commit more resources to those markets.  
Product Defects.
 In the event any of the Company's products prove defective, the Company may be required to redesign or recall products.  While the Company has not had a recall to date, a redesign or recall could cause the Company to incur significant expenses, disrupt sales and adversely affect the reputation of the Company and its products, any one or a combination of which could have a material adverse affect on the Company's financial performance.
Product Reliability.
The Company's products have not been in service for a sufficient time to determine their long term reliability.  Failure of a substantial number of the Company's products would result in severe damage to the Company's reputation. 
Patents and Trademarks.
  The Company has applied for certain patents and trademarks.  While the Company believes that patent rights are important and will protect the Company's proprietary rights in the patented technologies, there can be no assurance that any future patent application will ultimately mature as an issued patent, or that any present or future patents of the Company will prove valid or provide meaningful protection from competitors.  See "Business - Patents and Trademarks."
Reliance upon Directors and Officers.
The Company is largely dependent, at the present, upon the personal efforts and abilities of its officers and directors.  See "Business" and "Management." 
Issuance of Additional Shares.
Approximately 53,921,554 shares of Common Stock or 71.9% of the 75,000,000 authorized shares of Common Stock of the Company are un-issued.  The Board of Directors has the power to issue such shares, subject to shareholder approval, in some instances.  Although the Company presently has no commitments, contracts or intentions to issue any additional shares to other persons, other than in the exercise of options and warrants, the Company may in the future attempt to issue shares to acquire products, equipment or properties, or for other corporate purposes.  Any additional issuance by the Company, from its authorized but un-issued shares, would have the effect of diluting the interest of existing shareholders.
 
 
-9-
Indemnification of Officers and Directors for Securities Liabilities.
 The Company's Bylaws provide that the Company will indemnify any Director, Officer, agent and/or employee as to those liabilities and on those terms and conditions as are specified in laws of the state of Nevada.  Further, the Company may purchase and maintain insurance on behalf of any such persons whether or not the corporation would have the power to indemnify such person against the liability insured against.  The foregoing could result in substantial expenditures by the Company and prevent any recovery from such Officers, Directors, agents and employees for losses incurred by the Company as a result of their actions.  Further, the Company has been advised that in the opinion of the Securities and Exchange Commission, indemnification is against public policy as expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable. 
Cumulative Voting, Preemptive Rights and Control.
  There are no preemptive rights in connection with the Company's Common Stock.  Shareholders may be further diluted in their percentage ownership of the Company in the event additional shares are issued by the Company in the future. Cumulative voting in the election of Directors is not provided for.  Accordingly, the holders of a majority of the shares of Common Stock, present in person or by proxy, will be able to elect all of the Company's Board of Directors.
No Dividends Anticipated.
At the present time the Company does not anticipate paying dividends, cash or otherwise, on its Common Stock in the foreseeable future.  Future dividends will depend on earnings, if any, of the Company, its financial requirements and other factors.
Penny Stock - Additional Sales Practice Requirements.
  The Company's common stock is covered by a Securities and Exchange Commission rule that imposes additional sales practice requirements on broker-dealers who sell such securities to persons other than established customers and accredited investors, generally institutions with assets in excess of $5,000,000 or individuals with net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly with their spouse.  For transactions covered by the rule, the broker-dealer must make a special suitability determination for the purchaser and transaction prior to the sale.  Consequently, the rule may affect the ability of broker-dealers to sell the Company's securities and also may affect the ability of purchasers of the Company's stock to sell their shares in the secondary market. 

ITEM 2.       DESCRIPTION OF PROPERTIES.

The Company does not currently own any real property. The Company's corporate offices are located in Winston-Salem, North Carolina.  Office facilities are located  at 101 North Chestnut Street and at Reynolda Road.  The primary mailing address is 101 North Chestnut Street, Suite 307, Winton-Salem NC 27101. The company has a total of 1300 sq. ft. leased and the main telephone number is   (336) 722-2254.  Monthly rent is $1,155, payable to Wake Forest University. 
 
 
-10-
**ITEM 3.       LEGAL PROCEEDINGS.**
There are no material legal proceedings to which the Company is subject to or which are anticipated or threatened.
**ITEM 4.       SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.**
There were no matters submitted to the Shareholders during the fourth quarter of 2003.
**PART II

ITEM 5.       MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDERS MATTERS.**
The Company's Common Stock was quoted on the Bulletin Board operated by the National Association of Securities Dealers, Inc.  ("OTCBB") under the symbol "ALRT."  Summary trading by quarter for the 2003 and 2002 fiscal years are as follows:

**Fiscal Quarter**High Bid [1]**Low Bid [1]**
**2003
 
 
Fourth QuarterThird QuarterSecond QuarterFirst Quarter
0.150.170.260.39
0.070.090.140.15**2002
 
 
Fourth QuarterThird QuarterSecond QuarterFirst Quarter
0.290.310.430.30
0.160.120.090.07

[1] 
These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.
At December 31, 2003, there were 21,078,446 common shares of the Company issued and outstanding.  

At December 31, 2003, there were 64 holders of record including common shares held by brokerage clearing houses, depositories or otherwise in unregistered form.  The beneficial owners of such shares are not known by the Company.

 

 

-11-

No cash dividends have been declared by the Company nor are any intended to be declared.  The Company is not subject to any legal restrictions respecting the payment of dividends, except that they may not be paid to render the Company insolvent.  Dividend policy will be based on the Company's cash resources and needs and it is anticipated that all available cash will be needed for working capital.

There are no securities authorized for issuance under any equity compensation plans.
**ITEM 6.       MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS

General**
ALR Technologies Inc's. business is focused on enhancement of disease management programs and health management programs through improved medication adherence with patient reminder products, monitoring of medication adherence and intervention systems when lack of adherence is apparent and the patient may be at risk.  The primary business markets targeted by ALR Technologies are the providers of health insurance and the providers of disease management services.  Health and disease management cannot achieve desired results unless the targeted individuals are compliant with their medications and unless there is timely intervention when they are not compliant and are deemed at risk.  

ALR Technologies also targets pharmaceutical manufacturers, clinical research organizations, pharmacy retailers and pet medications providers. The largest potential for sustainable long term growth and value generation lies with the market segments that have the most influence on the end-user and the most to gain from improved health results---and these market segments are the health insurance provider and the disease management companies they utilize.  The health insurance provider industry has the potential of reducing costs substantially through successful medication compliance programs.  Industry data reports that over $100 billion annually in health care costs are due to people not taking medications as directed.  

ALR Technologies is attempting to grow a network of industry professionals who see the need for the ALR Tech products and systems.  Discussions with several of the leading health care providers, disease management companies and major pharmaceutical manufacturers have been achieved.   Relationships have been established that have the potential for significant business development, but medication compliance products and systems are relatively new to these industries and recognition, acceptance and use comes slowly.

The market that ALR Technologies products and services address is undeveloped in the industry.  This situation provides significant upside potential in growing a new market but also comes with significant costs in time for market development and resource requirements.  

 

 

-12-

The company desires to team with leading companies in select market segments and as such has been seeking strategic alliances that would serve to enhance the ability of ALR Technologies to generate sales and growth as well as enhance the sales performance of the participating company.  Discussions with some of the major pharmaceutical companies as well as health insurance providers and disease management companies are ongoing.  Vision care medications and the pet medication market are two other segments where discussions are currently underway.  It is also likely that pilot trials by independent organizations will be initiated in the first half of 2004 that will be set up to determine outcome results from the use of ALRT medication reminder products.  Outcome results to be determined will likely include a.) change in medication adherence, b.) change in health results for the patients, and c.) change in total cost of care.
**Revenue**
Revenues increased 268% to $175,820 in 2003 from $47,696 for 2002. The network building efforts began to generate business in the 4th quarter of 2003 as one pharmaceutical manufacturer placed an order in November and product shipped in December and a second pharmaceutical manufacturer placed an order in late December.  Approximately $130,000 of the total sales for 2003 came in the 4th Quarter.  Orders placed that are to be shipped in first quarter 2004 will ensure 1st quarter 2004 sales in excess of $200,000, or a minimum increase of 390% over 1st Quarter 2003.  Progress underway with health insurance providers, disease management companies and other potential market segments bring expectations of continued growth through all quarters of 2004.  
**Product Development**
The Company continued to focus development efforts on their interactive compliance monitoring and intervention system (AIRS) as well as their PC500 medication compliance product that will remind as well as provide a message on a screen informing the person the precise actions to take at the time of each reminder event. During 2003, the company received requests or inquiries for additional products.  Included are reminder products for people to change contact lens for 7 day, 14 day or 30 day throw-away lenses and also for weekly administered medications.
**Operating Capital**
ALR Technologies revenue from sales is not at a level to pay for operating costs and as such the management of ALR Tech have volunteered to have their compensation deferred until cash flow allows for payment and creditors have agreed to additional stock option grants in return for deferred payment on interest in some cases and agreements of note extensions in other cases.   Although the prospects for cash flow from sales of products and services to increase through 2004, there is no certainty of this, and if sales do continue to increase there is no certainly that it will reach the level necessary to cover operating costs and debt load.  

 

 

-13-
**Management Compensation**
Management has accepted deferred payment on compensation, deferred payment on interest on loans they have made to the Company and have paid Company bills and expenses without repayment; all to help ensure the Company's survival.  In return, the Company's directors plan to reward the participating personnel at a time when business objectives are met, with stock option grants. 
**Operating Issues**
The Company has expended significant efforts introducing its Human Prescription Reminders to specified retail chains, pharmaceutical manufacturers, Contract Research Organizations, Health Management Organizations, Pharmacy Benefits Managers and certain clinics treating specific disease conditions.  Sales to December 31, 2003 have not been sufficient for the Company to realize its investment in these inventories.  Management plans to recover its investment in inventories through sales via the channels indicated above as the recognition of the need for medication adherence products increases.    This may take some time to achieve, if at all, and, as a result, management has recorded an inventory provision of $160,000 at December 31, 2003 in respect of its Human Reminder inventory.  The alternate use of this inventory is limited and, accordingly, if management is not successful in its plans, they may be required to further write-down its investment in inventories in the near term.  The outcome of this matter cannot be predicted at this time.
**Related Party Transactions**
On January 22, 2001, Christine Kan, wife of Sidney Chan, Chief Executive Officer and a Director of the Company loaned the Company $2,000,000.  The loan bears interest at one percent per month and is due on demand.  As additional consideration for the loan, the Company irrevocably committed to issue to Ms. Kan warrants to purchase 4,000,000 shares of the Company's common stock at an exercise price of $0.25 per share expiring December 31, 2005.

On November 24, 2003 and December 17, 2003, Christine Kan, wife of Sidney Chan, Chief Executive Officer and a Director of the Company loaned the Company $150,000 and $30,000, respectively.  The loans bear interest at one percent per month and are due on demand.  As additional consideration for the loan, the Company irrevocably committed to issue to Ms. Kan options to purchase 720,000 shares of the Company's common stock at an exercise price of $0.25 per share expiring December 31, 2008.

On May 30, 2003, Stan Cruitt, President of the Company loaned the Company $30,000 and on June 10 , 2003, Mr. Cruitt loaned the Company an additional $12,000 for a total of $42,000.  The loans bear interest at one percent per month and are due on demand.  As additional consideration for the loan, the Company irrevocably committed to issue to Mr. Cruitt options to purchase 168,000 shares of the Company's common stock at an exercise price of $0.25 per share expiring December 31, 2008.

On March 13, 2003, Sidney Chan, Chairman and Chief Executive Officer of the Company loaned the Company $151,000 in Canadian dollars (US$116,500 equivalent).  The loan bear interest at one percent per month and are due on demand.  

 

 

-14-
**Results of Operations - December 31, 2003 compared to December 31, 2002**
Sales for the year ended December 31, 2003 were $175,820 and cost of goods sold was $127,471 as compared to $47,696 and $35,142, respectively for the year ended December 31, 2002.  Sales were up in fiscal 2003 as a result of the decision to de-emphasize sales and marketing activities of Pet Reminders and focus on Human Reminders which were only introduced in the latter part of 2002.

Product development costs increased to $173,828 in 2003 versus $165,973 for the year ended December 31, 2002.  This decrease relates primarily to development costs incurred for the ALRT Med Reminder and the ongoing development of the ALRT Interactive Reminder System.

Interest expense was increased to $1,410,509 for the year ended December 31, 2003 as compared with $1,344,422 for the year ended December 31, 2002 as the Company relied on increased debt financing in the year to cover operating costs.  Included in the total reported interest is a non-cash amount of $795,806 related the amortization of the discount arising form the stock options and warrants irrevocably committed to be issued in consideration for promissory notes, down from $883,051 for the year ended December 31, 2002.

The Company incurred professional fees of $61,684 for the year ended December 31, 2003 as compared with $86,256 for the year ended December 31, 2002.  The higher level in 2002 is partly attributable to higher legal fees related to legal actions resolved in that year and partly due to increased accounting costs related to a higher level of sales activity in 2001.

Rent was up slightly in fiscal 2003 to $35,980 from $34,311 for the year ended December 31, 2002.

The selling, general and administrative expenses were $946,815 for the year ended December 31, 2003 as compared to $880,888 for the year ended December 31, 2002.  These totals include $109,000 (December 31, 2001 - $54,500) for a non-cash amount related to the value of stock options committed to be issued for selling, general and administrative services in the year.  The increase in cash amounts from $826,388 to $837,815 relates primarily to the increase in compensation and other costs of marketing.

The loss of $2,775,899 for the year ended December 31, 2003 was up from a loss of $2,503,951 for the year ended December 31, 2002.  The increase in the net loss is primarily due to the inventory provision in the amount of $160,000 in the current year.

 Accounts receivable were $128,903 at December 31, 2003 as compared with $17,220 at December 31, 2002.  

Inventories increased to 276,583, before a provision of $160,000, at December 31, 2003 from $189,216 at December 31, 2002 as the Company began building inventories of its Human Med Reminders.

 

 

-15-

Prepaids, expenses and deposits were $nil at December 31, 2003 as compared to $132,227 at December 31, 2002.  This decrease was primarily attributable to production deposits held by Tandy Electronics (Far East) Ltd. at December 31, 2002, which were drawn down against inventory shipments in January and February 2003.

Accounts payable and accrued liabilities increased to $2,161,133 at December 31, 2003 from $1,230,275 at December 31, 2002.

Other debt financing increased to $6,044,315 at December 31, 2003 from $4,882,730 at December 31, 2002 as the Company was able to obtain debt financing from several sources in order to continue operating and provide funds for product development
***December 31, 2002 compared to December 31, 2001 

Sales for the year ended December 31, 2002 were $47,696 and cost of goods sold was $35,142 as compared to $364,328 and $194,320, respectively for the year ended December 31, 2001.  Sales were down in fiscal 2002 as a result of the decision to de-emphasize sales and marketing activities of Pet Reminders and focus on Human Reminders which were only introduced in the latter part of 2002.

Product development costs increased to $165,973 in 2002 versus $41,393 for the year ended December 31, 2001.  This increase relates primarily to development costs incurred for the ALRT Med Reminder and the ongoing development of the ALRT Interactive Reminder System.

Interest expense was up to $1,344,422 for the year ended December 31, 2002 as compared with $869,014 for the year ended December 31, 2001 as the Company relied on increased debt financing in the year to cover operating costs.  Included in the total reported interest is a non-cash amount of $883,051 related the amortization of the discount arising form the stock options and warrants committed to be issued in consideration for promissory notes, up from $550,333 for the year ended December 31, 2001.

The Company incurred professional fees of $86,256 for the year ended December 31, 2002 as compared with $125,466 for the year ended December 31, 2001.  The higher level in 2001 is partly attributable to higher legal fees related to legal actions resolved in that year and partly due to increased accounting costs related to a higher level of sales activity in 2001.

Rent was down slightly in fiscal 2002 to $34,311 from $39,411 for the year ended December 31, 2001.

The selling, general and administrative expenses were $880,888 for the year ended December 31, 2002 as compared to $1,444,384 for the year ended December 31, 2001.  These totals include $54,500 (December 31, 2001 - $404,800) for a non-cash amount related to the value of stock options committed to be issued for selling, general and administrative services in the year.  The decrease in cash amounts from $1,039,584 to $826,388 relates primarily to the decrease in compensation and other costs of marketing.

 

 

-16-

The loss of $2,503,951 for the year ended December 31, 2002 was up from a loss of $3,681,189 for the year ended December 31, 2001.  The decrease in the net loss is primarily due to the write-down of inventory in the amount of $1,328,313 in the prior year as aggregate operating expenses were relatively unchanged.

Accounts receivable were $17,220 at December 31, 2002.  There were only nominal accounts receivable at December 31, 2001.

Inventories increased to $189,216 at December 31, 2002 from $nil at December 31, 2001 as the Company began building inventories of its Human Med Reminders.

Prepaids, expenses and deposits were $132,227 at December 31, 2002 as compared to $35,235 at December 31, 2001.  This increase was primarily attributable to production deposits held by Tandy Electronics (Far East) Ltd. at December 31, 2002 which were drawn down against inventory shipments in January and February 2003.

Accounts payable and accrued liabilities increased slightly to $1,230,275 at December 31, 2002 from $1,161,812 at December 31, 2001.

Other debt financing increased to $4,882,730 at December 31, 2001 from $3,406,579 at December 31, 2001 as the Company was able to obtain debt financing from several sources in order to continue operating and provide funds for product development.
**Liquidity and Capital Resources.
*Cash Balances*
At December 31, 2003, the Company's cash balance was $29,852 compared to $979 at December 31, 2002.
***Short and Long Term Liquidity*
With respect to the Company's short-term liquidity, the Company's "current ratio" (current assets divided by current liabilities) as of December 31, 2003 was $0.03 compared to $0.06 as of December 31, 2002.  The greater the current ratio, the greater the short-term liquidity of the Company.

The Company raised $920,000 in debt financing in 2003 for working capital.

The Company plans additional debt financing in the short run and has raised $30,000 subsequent to December 31, 2003.  These proceeds were put toward working capital.

A significant portion of the Company's debt financing is either due on demand or has a maturity date of less than one year.  The Company will seek to obtain creditor's consent to delay repayment of these loans until it is able to replace this financing with funds generated by operations, replacement debt or from equity financings through private placements or the exercise of options and warrants.  While the Company's creditors have agreed to extend repayment deadlines in the past,

 

 

-17-

there is no assurance that they will continue to do so in the future.  Failure to obtain either replacement financing or creditor consent to delay the repayment of existing financing could result in the Company having to cease operations.
**Cash Used in Operating Activities**
Cash used by the Company in operating activities during the year ended December 31, 2003 totaled $841,127 The Company incurred a net loss of $2,755,899 for the year ended December 31, 2002 as compared to a loss of $2,503,951 for the year ended December 31, 2003.  Cash used by the Company in operating activities during the year ended December 31, 2002 totaled $1,797,410.
**Cash Proceeds from Financing Activities**
During the year ended December 31, 2003, the Company arranged $920,000 in debt financing.  $50,000 of the proceeds from these financings was used to enable the Company to repay existing debt.  This debt bears interest at 1% per month.  Promissory notes with a face amount of $5,723,500 originally due at various dates in 2003 and are now due on demand.  Promissory notes with a face amount $66,500 are due June 1, 2004.  In consideration for loans or the extension of their due dates, the Company has committed to issue options to acquire a total of 5,849,000 shares of the Company at $0.25 per share with various expiration dates in 2008.  The fair value of these options has been estimated and recognized in the financial statements as additional interest expense.

During the year ended December 31, 2002, the Company arranged $1,870,000 in debt financing.  $131,000 of the proceeds from these financings was used to enable the Company to repay existing debt.  This debt bears interest at 1% per month with $1,350,000 originally due December 31, 2002 (extended with lenders' consent to April 30, 2003) and $520,000 due December 31, 2003.  In consideration for these loans, the Company has committed to issue options to acquire a total of 11,580,000 shares of the Company at $0.25 per share with various expiration dates in 2007.  The fair value of these options has been estimated and recognized in the financial statements as additional interest expense.
**Critical Accounting Policies**
The preparation of our financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reported periods.  Actual results may differ from these estimates under different assumptions or conditions.  We believe the accounting polices that are most critical to our financial condition and results of operations and involve management's judgment and/or evaluation of inherent uncertain factors are as follows:

 

 

-18-
*Basis of Presentation.  The financial statements have been prepared on the going concern basis, which assumes the realization of assets and liquidation of liabilities in the normal course of operations.  If the Company were not to continue as a going concern, it would likely not be able to realize on its assets at values comparable to the carrying value or the fair value estimates reflected in the balances set out in the preparation of the financial statements.  As described elsewhere in this annual report, at December 31, 2003 there are certain conditions that exist which raise substantial doubt about the validity of this assumption.  The Company's ability to continue as a going concern is dependent upon continued financial support of its creditors and its ability to obtain financing to repay its current obligations and fund working capital and its ability to achieve profitable operations.  The Company will seek to obtain creditors consent to delay repayment of its outstanding promissory notes payable until it is able to replace this financing with funds generated from operations, replacement debt or from equity financing through private placements or the exercise of options and warrants.  While the Company's creditors have agreed to extend repayment deadlines in the past, there is no assurance that they will continue to do so in the future.    Management plans to obtain financing through the issuance of additional debt, the issuance of shares on the exercise of options and warrants and through future common share private placements.  Management hopes to realize sufficient sales in future years to achieve profitable operations.  Failure to achieve management's plans may result in the Company curtailing operations or writing assets and liabilities down to liquidation values, or both.
*Inventories.  Inventories are recorded at the lower of cost, determined on a weighted average cost basis, and net realizable value.  
*Options and warrants issued in consideration for debt.  The Company allocates the proceeds received from long term debt between the liability and the options and warrants issued in consideration for the debt, based on their relative fair values, at the time of issuance.  The amount allocated to the options or warrants is recorded as additional paid in capital and as a discount to the related debt.  The discount is amortized to interest expense on a yield basis over the term of the related debt.
*Revenue recognition.  The Company recognizes sales revenue at the time of delivery when title has transferred to the customer, persuasive evidence of an arrangement exists, the fee is fixed and determinable and the sales proceeds are collectible.  Provisions are recorded for product returns based on historical experience.  Sales revenue, in transactions for which the Company does not have sufficient historical experience, are recognized when the return privilege period has expired.
*Stock-based compensation.  The Company accounts for its employee stock-based compensation arrangements in accordance with provisions of Accounting Principles Board ("APB") Opinion No. 25. "*Accounting for Stock Issued to Employees*", and related interpretations.  As such, compensation expense for stock options, common stock and other equity instruments issued to non-employees for services received based upon the fair value of the equity instruments issued, as the services are provided and the securities earned.

 

 -19- 
 
**ITEM 7.       FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

INDEPENDENT AUDITORS' REPORT 	
F-1
 
 
Balance Sheets	
F-2
Statements of Loss	
F-3
Statement of Shareholders' Deficiency and Comprehensive Loss
F-4
Statements of Cash Flows	
F-5
 
 
NOTES TO THE FINANCIAL STATEMENTS	
F-6

 

 

 

 

 

 

 

 

 -20- 
 

 
**INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders of ALR Technologies Inc.

We have audited the accompanying balance sheets of ALR Technologies Inc. as of December 31, 2003 and 2002 and the related statements of loss, shareholders' deficiency and comprehensive loss, and cash flows for the years then ended.  These financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on these financial statements based on our audits.  

We conducted our audits in accordance with auditing standards generally accepted in the United States of America.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2003 and 2002 and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  The Company has suffered recurring losses, negative cash flows from operations and has a net capital deficiency, factors which raise substantial doubt about the Company's ability to continue as a going concern.  Management's plans in regards to these matters are also described in note 1.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

 

/s/  KPMG LLPKelowna, CanadaApril 6, 2004
 

F-1

-21-

**ALR TECHNOLOGIES INC.
Balance Sheets
$United States 
December 31, 2003 and 2002
2003 
2002 
Assets     
Current assets:      
Cash
$
29,852 
$
979 
Accounts receivable, net of allowance of $563 (2002 - $563) 
128,903  
17,220 
Inventories (note 3) 
113,633  
189,216 
Prepaid expenses, deposits and advances 
- 
132,227   
272,388  
339,642
Fixed assets (note 4) 
8,210 
11,191       
$ 
280,598 
$ 
350,833       
Liabilities and Shareholders' Deficiency     
Current liabilities:      
Accounts payable and accrued liabilities
$
2,161,133 
$
1,230,275 
Promissory notes payable to a relative of a director (note 5) 
2,680,000  
2,500,000 
Promissory notes payable to directors (note 5) 
558,500  
400,000 
Current portion of promissory notes payable (note 5) 
2,534,903 
1,711,818   
7,934,536  
5,842,093      
Promissory notes payable (note 5) 
270,912  
270,912
Shareholders' deficiency:      
Capital stock      
75,000,000 common shares with a par value of $0.001     
per share authorized, 21,078,446 issued     
(2002 - 21,078,446 issued) 
21,078  
21,078 
Additional paid-in capital 
5,491,835  
4,878,614 
Deficit 
(13,474,927)  
(10,699,028) 
Accumulated other comprehensive income      
Cumulative translation adjustment 
37,164 
37,164   
(7,924,850)  
(5,762,172)
Basis of presentation (note 1)     
Commitments (note 6)     
Related party transactions (notes 5 and 7) 
$ 
280,598 
$ 
350,833       
See accompanying notes to financial statements     
On behalf of the Board:           
Sidney Chan 
Director     
Stanley Cruitt 
Director     
 

F-2

-22-

**ALR TECHNOLOGIES INC.
Statements of Loss
$United States 
Years ended December 31, 2003 and 2002
2003 
2002             
Sales
$
175,820 
$
47,696      
Cost of sales      
Cost of goods sold
127,471  
35,142 
Loss on write-down of inventories (note 3) 
160,000 
- 
287,471 
35,142         
(111,651)  
12,554        
2,981  
2,956
Operating expenses      
Depreciation 
173,828  
165,973 
Development costs 
32,451  
1,699 
Foreign exchange loss 
1,410,509  
1,344,422 
Interest on promissory notes payable 
61,684  
86,256 
Professional fees 
35,980  
34,311 
Rent 
946,815  
880,888 
Selling, general and administrative 
946,815
880,888
2,664,248 
2,516,505 
Loss 
$ 
(2,775,899) 
$ 
(2,503,951)             
Loss per share, basic and diluted 
$ 
(0.13) 
$ 
(0.12)             
Weighted average shares outstanding, basic and diluted 
21,078,446 
21,078,446             
See accompanying notes to financial statements       
 

F-3

-23-

**ALR TECHNOLOGIES INC.
Statement of Shareholders' Deficiency and Comprehensive Loss
$United States 
Years ended December 31, 2003 and 2002  
Capital Stock 
Accumulated    
Additional 
Other
Total 
Number of 
Paid In 
Comprehensive
Shareholders'
shares 
Amount 
Capital 
Deficit 
Income 
Deficiency        
Balance, December 31, 2001
21,078,446
$
21,078
$
3,678,214
$
(8,195,077)
$
37,164
$
(4,458,621)            
Comprehensive cost of stock           
options issued for services
- 
- 
54,500 
- 
- 
54,500            
Financing cost of stock options            
and warrants issued in           
consideration for promissory notes
- 
- 
1,145,900 
- 
- 
1,145,900            
Comprehensive income (loss):           
Loss 
- 
- 
- 
(2,503,951) 
- 
(2,503,951)             
Balance, December 31, 2002
21,078,446 
21,078 
4,878,614 
(10,699,028) 
37,164 
(5,762,172)            
Compensation cost of stock           
options issued for services
- 
- 
109,000 
- 
- 
109,000            
Financing cost of stock options           
issued in consideration for           
promissory notes
- 
- 
504,221 
- 
- 
504,221            
Comprehensive income (loss):           
Loss 
- 
- 
(2,775,899) 
- 
(2,775,899) 
Balance, December 31, 2003 
21,078,446 
$ 
21,078 
$ 
5,491,835 
$ 
(13,474,927) 
$ 
37,164 
$ 
(7,924,850)              
See accompanying notes to financial statements
 

 

 

 

F-4

-24-

**ALR TECHNOLOGIES INC.
Statements of Cash Flows
$United States 
Years ended December 31, 2003 and 2002
2003 
2002    
Cash flows from operating activities (note 9):     
Cash received from customers
$
64,137
$
31,475 
Cash paid to suppliers and service providers 
(745,979) 
(1,575,040) 
Interest paid 
(159,285) 
(253,845) 
Income taxes paid 
- 
-  
Net cash used by operating activities 
(841,127) 
(1,797,410)      
Cash flows from financing activities:     
Proceeds from promissory notes 
920,000 
1,870,000 
Repayment of promissory notes 
(50,000) 
(131,000)  
Net cash provided by financing activities 
870,000 
1,739,000      
Cash flows from investing activities:    
Purchase of fixed assets 
- 
(6,316)       
Increase (decrease) in cash 
28,873 
(64,726)      
Cash, beginning of year 
979 
65,705       
Cash, end of year 
$ 
29,852 
$ 
979             
Non-cash financing and investing activities:     
Compensation cost of options issued for services
$
109,000
$
54,500 
Financing cost of options and warrants issued in consideration for    
promissory notes or their due date extension 
504,221 
1,145,900 
$ 
613,221 
$ 
1,200,400    
See accompanying notes to financial statements. 
 

 

F-5

 

-25-

**ALR TECHNOLOGIES INC.
Notes to Financial Statements
$United States 
Years ended December 31, 2003 and 2002
ALR Technologies Inc. ("the Company" or "ALR Tech.") was incorporated under the laws of the State of Nevada on May 24, 1987.  The Company is listed on the National Association of Security Dealers Over-the-Counter Bulletin Board.  The principal business activity of the Company includes the design, marketing, and distribution of medical reminder compliance devices.  Approximately 85% of the Company's 2003 sales were from two customers (68% and 17%, respectively) in the United States of America while approximately 88% of the Company's 2002 sales were from one customer in the United States of America.  
Basis of presentation:
These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America on a going concern basis which assumes the realization of assets and the discharge of liabilities in the normal course of operations for the foreseeable future.
The Company's ability to continue as a going concern is dependent upon continued financial support of its creditors and its ability to obtain financing to repay its current obligations and fund working capital and its ability to achieve profitable operations.  The Company will seek to obtain creditors consent to delay repayment of its outstanding promissory notes payable until it is able to replace this financing with funds generated from operations, replacement debt or from equity financing through private placements or the exercise of options and warrants.  While the Company's creditors have agreed to extend repayment deadlines in the past, there is no assurance that they will continue to do so in the future.  Management plans to obtain financing through the issuance of additional debt, the issuance of shares on the exercise of options and warrants (note 6) and through future common share private placements.  Management hopes to realize sufficient sales in future years to achieve profitable operations.  The resolution of the going concern issue is dependent upon the realization of management's plans.  There can be no assurance provided that the Company will be able to raise sufficient debt or equity capital from the sources described above on satisfactory terms.  If management is unsuccessful in obtaining financing or achieving profitable operations, the Company will be required to cease operations.  The outcome of these matters cannot be predicted at this time.
These financial statements do not give effect to any adjustments which could be necessary should the Company be unable to continue as a going concern and, therefore, be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts differing from those reflected in the financial statements.
Significant accounting policies:
a)   Foreign currency transactions:
The Company's functional currency is the United States dollar.  Transactions in foreign currencies are translated into United States dollars at the rates in effect on the transaction dates.  Exchange gains or losses arising on translation or settlement of foreign currency monetary items are included in the statement of loss.
 
F-6
-26-

**ALR TECHNOLOGIES INC.
Notes to Financial Statements
$United States 
Years ended December 31, 2003 and 2002Significant accounting policies (continued):
b)   Inventories
Inventories are recorded at the lower of cost, determined on a weighted average cost basis, and net realizable value.  
c)   Fixed assets
Fixed assets are recorded at cost.  Depreciation is provided using the following method and annual rates:
     
Asset 
Method 
Rate   
Computer equipment
Declining balance
30% 
Office equipment
Declining balance
20% 
d)   Options and warrants issued in consideration for debt

The Company allocates the proceeds received from long term debt between the liability and the attached options and warrants issued in consideration for the debt, based on their relative fair values, at the time of issuance.  The amount allocated to the options or warrants is recorded as additional paid in capital and as a discount to the related debt.  The discount is amortized to its face value as interest expense on a yield basis over the term of the related debt.

e)   Revenue recognition

The Company recognizes sales revenue at the time of delivery when title has transferred to the customer, persuasive evidence of an arrangement exists, the fee is fixed and determinable and the sales proceeds are collectible.  Provisions are recorded for product returns based on historical experience.  Sales revenue, in transactions for which the Company does not have sufficient historical experience, are recognized when the return privilege period expires.

 

F-7

-27-

**ALR TECHNOLOGIES INC.
Notes to Financial Statements
$United States 
Years ended December 31, 2003 and 2002Significant accounting policies (continued):
f)   Stock-based compensation
The Company accounts for its employee stock-based compensation arrangements in accordance with provisions of Accounting Principles Board ("APB") Opinion No. 25. "*Accounting for Stock Issued to Employees*," and related interpretations.  As such, compensation expense for stock options, common stock and other equity instruments issued to non-employees for services received is based upon the fair value of the equity instruments issued, as the services are provided and the securities earned.
SFAS No. 123"*Accounting for Stock-Based Compensation*", requires entities that continue to apply the provisions of APB Opinion No. 25 for transactions with employees to provide pro forma net earnings (loss) and pro forma earnings (loss) per share disclosures for employee stock option grants as if the fair-value-based method defined in SFAS No. 123 had been applied to these transactions.  
For the years ended December 31, 2003 and 2002, no stock options were granted or irrevocably committed to be issued to employees or directors.  Had the Company determined compensation costs based on the fair value of its stock options at the grant date under SFAS No. 123, the Company's loss for the year would have been increased to the pro forma amounts below:
  
2003 
2002  
Loss  
As reported
$
2,775,899
$
2,503,951  
Pro forma
$
2,775,899
$
2,503,951 
Loss, per share, basic and diluted      
As reported
$
0.13
$
0.12 
Pro forma 
$ 
0.13 
$ 
0.12  
g)   Income taxes

Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carryforwards that are available to be carried forward to future years for tax purposes.  

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  When it is not considered to be more likely than not that a deferred tax asset will be realized, a valuation allowance is provided for the excess.

 

F-8

 

-28-

**ALR TECHNOLOGIES INC.
Notes to Financial Statements
$United States 
Years ended December 31, 2003 and 2002Significant accounting policies (continued):
g)   Income taxes (continued)
Although the Company has consolidated loss carry forwards of approximately $7,600,000 available to 2005 to 2010 to reduce future income for tax purposes, no amount has been reflected on the balance sheet for deferred income taxes as any deferred tax asset has been fully offset by a valuation allowance.
h)   Loss per share
Basic loss per share has been calculated using the weighted average number of common shares issued and outstanding during the year.  As the Company has a loss in each of the years presented, basic and diluted loss per share are the same.
i)   Use of estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Significant areas requiring management estimates include the recoverable amount of the Company's inventories, compensation costs of stock options issued for services and the financing costs of stock options and warrants issued in consideration for promissory notes payable.  Actual results could differ from those estimates.
j)   Commitments and contingencies
Liabilities for loss contingencies, arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.  Recoveries from third parties which are probable of realization are separately recorded, and are not offset against the related liability, in accordance with Financial Accounting Standards Board Interpretation No. 39, "Offsetting of Amounts Related to Certain Contracts."
k)   Recent accounting pronouncements
In July 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities. Statement 146 requires companies to recognize costs associated with exit or disposal activities when they are incurred rather than at the date of a commitment to an exit or disposal plan. Statement 146 supersedes accounting guidance previously provided by EITF Issue No. 94-3, Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring). SFAS No. 146 is applied prospectively to exit or disposal activities initiated after December 31, 2002. The adoption of this statement did not have a material impact on the Company's financial position or results of operations. 
 
 
F-9
-29-

**ALR TECHNOLOGIES INC.
Notes to Financial Statements
$United States 
Years ended December 31, 2003 and 2002Significant accounting policies (continued):
k)   Recent accounting pronouncements (continued)
In November 2002, the FASB issued Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others. Interpretation No. 45 elaborates on the existing disclosure requirements for most guarantees, including loan guarantees such as standby letters of credit. It also clarifies that at the time a company issues a guarantee, the company must recognize and record an initial liability for the fair value of the obligations it assumes under that guarantee and must disclose that information in its interim and annual financial statements.   The disclosure provisions are effective for periods ending after December 15, 2002.  The initial recognition and initial measurement provisions apply on a prospective basis to guarantees issued or modified after December 31, 2002. Implementation of this interpretation did not have a material effect on the Company's financial position or results of operations. 
During January 2003, the FASB issued, and subsequently revised, its Interpretation No. 46, Consolidation of Variable Interest Entities. The interpretation addresses consolidation of certain entities in which equity investors do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties.  The Company will be required to apply the consolidation provisions of the interpretation as of the beginning of its second quarter of fiscal 2004.  Implementation of Interpretation No. 46, as revised, is not expected to have a material effect on the Company's financial position or results of operations. 
In May 2003, the FASB issued SFAS No. 150, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity. SFAS No. 150 requires that certain financial instruments issued in the form of shares that are mandatorily redeemable as well as certain other financial instruments be classified as liabilities in the financial statements. SFAS No. 150 is effective for financial instruments entered into or modified after May 31, 2003. The adoption of this statement did not have a material impact on the Company's financial position or results of operations.
 
 
 
F-10
-30-

**ALR TECHNOLOGIES INC.
Notes to Financial Statements
$United States 
Years ended December 31, 2003 and 2002Inventories:
  
2003 
2002   
Inventories, at cost
$
273,633
$
189,216 
Provision 
(160,000) 
-  
$ 
113,633 
$ 
189,216   
The Company has expended significant efforts introducing its Human Prescription Reminders to specified retail chains, pharmaceutical manufacturers, Contract Research Organizations, Health Management Organizations, Pharmacy Benefits Managers and certain clinics treating specific disease conditions.  Sales to December 31, 2003 have not been sufficient for the Company to realize its investment in these inventories.  Management plans to recover its investment in inventories through sales via the channels indicated above and through other, non-traditional sales channels not yet identified by management.  As a result, management has recorded a provision of $160,000 at December 31, 2003 in respect of its Human Reminder inventory.

The alternate use of this inventory is limited and, accordingly, if management is not successful in its plans, they may be required to further write-down its investment in inventories in the near term.  The outcome of this matter cannot be predicted at this time.
**Fixed assets:
 **2003    
Accumulated
Net book 
Cost 
depreciation 
value    
Computer equipment
$
16,028
$
10,827
$
5,201 
Office equipment 
5,566 
2,557 
3,009  
$ 
21,594 
$ 
13,384 
$ 
8,210  **2002   
Accumulated
Net book 
Cost 
depreciation 
value    
Computer equipment
$
16,028
$
8,598
$
7,430 
Office equipment 
5,566 
1,805 
3,761  
$ 
21,594 
$ 
10,403 
$ 
11,191         
 

F-11

 

-31-

**ALR TECHNOLOGIES INC.
Notes to Financial Statements
$United States 
Years ended December 31, 2003 and 2002Promissory notes payable:

2003 
2002 
Promissory notes payable to a relative of a director, secured by a general    
security agreement, with $500,000 bearing interest at the United States    
bank prime rate plus 1%, due on demand and $2,180,000 bearing interest    
at the 1% per month, due on demand
$
2,680,000
$
2,500,000
Promissory notes payable to a director of the Company, unsecured, with    
$350,000 bearing interest at 1% per month, due December 31, 2003,    
$42,000 bearing interest at 1% per month, due on demand and $50,000    
bearing interest at United States bank prime rate plus 1%, due on demand 
442,000 
400,000
Promissory notes payable to a director, unsecured, bearing interest at 1%    
per month due on demand  (CDN $151,000) 
116,500 
-
Promissory notes payable, unsecured, bearing interest at 1% per month,    
due December 31, 2003 
670,000 
670,000
Unamortized discount related to stock options issued in consideration for    
the promissory notes 
- 
(88,862)
Promissory notes payable, bearing interest at 1% per month, due on demand,    
unsecured with the exception of $50,000, which is secured by a guarantee    
from a director and relative of a director 
1,815,000 
1,350,000
Unamortized discount related to stock options issued in consideration for the    
promissory notes 
- 
(219,320)
Promissory note payable, unsecured, bearing interest at 1% per month, due    
June 1, 2004 
66,500 
-
Unamortized discount related to stock options issued in consideration for     
promissory notes due June 1, 2004 
(16,597) 
-
Promissory note payable to ALR Inc., unsecured, non-interest bearing,    
due July 17, 2005 
270,912 
270,912   
6,044,315 
4,882,730
Current portion due within one year     
Promissory notes payable to a relative of a director 
2,680,000 
2,500,000 
Promissory notes payable to directors 
558,500 
400,000 
Promissory notes payable to others 
2,534,903 
1,711,815 
5,773,403 
4,611,818      
$ 
270,912 
$ 
270,912       

 

F-12

 

-32-

**ALR TECHNOLOGIES INC.
Notes to Financial Statements
$United States 
Years ended December 31, 2003 and 2002
Promissory notes payable (continued):
Promissory notes totaling $1,020,000, due December 31, 2003 were not repaid and are now due on demand.  Promissory notes payable classified in current liabilities includes promissory notes payable with face amounts of $5,723,500 which are due on demand or which are overdue and are now due on demand.  The holders of the promissory notes payable have not taken action to demand repayment.
The aggregate maturities, in cash, of the face amount of promissory notes payable for each of the two years subsequent to December 31, 2003 are as follows:
2004 - $5,790,000; 2005 - $270,912.
6.Capital stock and additional paid in capital:
a)   Stock options:
The Company has irrevocably committed to grant options to purchase common shares of the Company as follows:
 
2003 
2002    
Weighted 
Weighted   
Average 
Average  
Number of
Exercise
Number of
Exercise 
Shares 
Price 
Shares 
Price    
Outstanding, beginning of year
28,460,000
$
0.25
16,740,000
$
0.25 
Granted
6,899,000
$
0.25
11,780,000
$
0.25 
Cancelled 
(100,000) 
$ 
0.50 
(60,000) 
$ 
0.25  
Outstanding, end of year 
35,259,000 
$ 
0.25 
28,460,000 
$ 
0.25   
The number of options outstanding and exercisable and the remaining contractual lives of the options at December 31, 2003 were as follows:

 
Options Outstanding     
Number of Options
Contractual Lives
Number of Options 
Exercise Price 
Outstanding 
Remaining 
Exercisable   
$ 
0.25 
35,259,000 
1.13 to 5.00 
33,259,000   
F-13

 

-33-

**ALR TECHNOLOGIES INC.
Notes to Financial Statements
$United States 
Years ended December 31, 2003 and 2002
Capital stock and additional paid in capital (continued):
a)   Stock options (continued):
During the year ended December 31, 2003, the Company irrevocably committed to grant 1,050,000 options to non-employees in exchange for services.  All of the options vested immediately.  The compensation cost related to the vested options has been estimated to be $77,000, which has been charged to selling, general and administrative expense.  The weighted average per share fair value of the options irrevocably committed to be issued in the year was $0.07.  The compensation cost recorded for the options was determined using the Black Scholes option pricing method, using the expected life of the options, a volatility factor of 135%, a risk free rate of 3.00% and no assumed dividend rate.
During the year ended December 31, 2003, 500,000 of options issued in the year ended December 31, 2001, vested upon the termination of a contract with a sales consultant to the Company for which no compensation cost had previously been recognized.  The related compensation cost has been estimated to be $32,000, and has been charged to selling, general and administrative expense.  Compensation cost was determined using the Black Scholes option pricing model, using the expected life of the options, a volatility factor of 102%, a risk free rate of 2.30% and no assumed dividend rate. Unvested options at December 31, 2003 consist of 2,000,000 options, which will vest based on the Company achieving certain sales targets.
During the year ended December 31, 2003, the Company irrevocably committed to grant 5,849,000 options, in consideration of promissory notes payable or of an extension to their original due dates.  All of the options vested immediately.  The related promissory note proceeds attributable to the options was estimated to be $504,221 of which $487,624 was amortized to interest expense during the year.  The weighted average per share fair value of the options irrevocably committed to be issued in the year was $0.09.  The fair value of the options was determined using the Black Scholes option pricing model, using the expected life of the options, volatility factors of 102% to 135%, risk free rates of 3.00% and no assumed dividend rate.  
During the year ended December 31, 2002, the Company irrevocably committed to grant 200,000 options to non-employees in exchange for services.  Of these options 100,000 vested immediately and 100,000 will vest based on the Company achieving certain performance targets.  The 100,000 unvested options expired prior to vesting in the year ended December 31, 2003 upon the termination of the contracts with these non-employees.  The compensation cost related to the vested options has been estimated to be $8,000, which has been charged to selling, general and administrative expense.  The weighted average per share fair value of the options irrevocably committed to be issued in the year was $0.08.  The compensation cost recorded for the options was determined using the Black Scholes option pricing model, using the expected life of the options, a volatility factor of 140%, a risk free rate of 5.00% and no assumed dividend rate.
 
 
F-14
 
-34-

**ALR TECHNOLOGIES INC.
Notes to Financial Statements
$United States 
Years ended December 31, 2003 and 2002
Capital stock and additional paid in capital (continued):
a)   Stock options (continued):
During the year ended December 31, 2002, 850,000 of the Company's previously issued options vested.  The related compensation cost has been estimated to be $46,500 and has been charged to selling, general and administrative expense.  The compensation cost recorded for the options was determined using the Black Scholes option pricing model, using the expected life of the options, a volatility factor of 140%, a risk free rate of 4.50% and no assumed dividend rate.
During the year ended December 31, 2002, the Company irrevocably committed to grant 11,580,000 options, in consideration of promissory notes payable or of an extension to their original due dates.  All of the options vested immediately.  The related promissory note proceeds attributable to the options was estimated to be $1,145,900 of which $853,718 was amortized to interest expense during 2002.  The weighted average per share fair value of the options irrevocably committed to be issued in the year was $0.10.  The fair value of the options was determined using the Black Scholes option pricing model, using the expected life of the options, volatility factors of 135% to 145%, risk free rates of 3.00% to 5.00% and no assumed dividend rate.  
b)   Warrants:
At December 31, 2003, the Company has 12,000,000 outstanding warrants (2002- 12,000,000).  Each warrant allows the holder to purchase one common share at an exercise price of $0.25 per share until December 31, 2005.
The Company has also agreed to extend the closing date of a proposed offering of up to 3,000,000 warrants at a price of $0.25 per warrant to June 30, 2004.  The 3,000,000 warrants will be exercisable into common shares at $0.001 per share.  These warrants will expire thirty days from the effective date of a registration statement filed with the United States Securities Commission registering the warrants and shares of common stock underlying the warrants.
Related party transactions:
At December 31, 2003 and 2002 the Company had the following related party balances and transactions:

2003 
2002 
Accounts payable and accrued liabilities
$
1,780,159
$
999,806
Promissory notes payable, face amount (note 5)
$
3,238,500
$
2,900,000
Interest on promissory notes payable
$
435,430
$
338,792
Management compensation to directors
$
319,800
$
319,800
Compensation paid to a relative of a director 
$ 
32,000 
$ 
-      
Interest paid on promissory notes payable to related parties, management compensation and compensation paid to a relative of a director have been recorded at the exchange amount, which is the amount agreed to by the parties.

F-15

-35-

**ALR TECHNOLOGIES INC.
Notes to Financial Statements
$United States 
Years ended December 31, 2003 and 2002
Financial instruments:
The fair values of cash, accounts receivable and accounts payable and accrued liabilities approximate their carrying values due to the relatively short periods to maturity of these instruments.  The fair value of the promissory notes payable approximate their carrying value because they bear interest at rates which are not significantly different from current market rates.  It is not possible to arrive at a fair value for the promissory note payable to ALR Inc. as the payment dates are not readily determinable.  It is not practical to determine a fair value for the promissory notes payable to directors or the promissory notes payable to a relative of a director due to the related party nature of these amounts and the absence of a ready market for such financial instruments.  Fair value has been estimated by discounting future principal and interest cash flows at the current rate available for the same or similar instrument.  The maximum credit risk exposure for all financial assets is the carrying value of the asset.
Reconciliation of loss to net cash used by operating activities:
   
2003 
2002    
Loss
$
(2,775,899)
$
(2,503,951)      
Adjustments to reconcile loss to net cash used by     
operating activities:      
Depreciation 
2,981 
2,956  
Compensation cost of options issued for services 
109,000 
54,500 
Amortization of discount resulting from options and warrants     
issued in consideration for promissory notes 
795,806 
883,051 
Increase in accounts receivable 
(111,683) 
(16,221) 
Decrease (increase) in inventories 
75,583 
(189,216) 
Decrease (increase) in prepaid expenses, deposits and     
advances 
132,227 
(96,992) 
Increase in accounts payable and accrued liabilities 
930,858 
68,463  
Net cash used by operating activities 
$ 
(841,127) 
$ 
(1,797,410)   
 

 

 

 

F-16

-36-
**ITEM 8.       CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.**
There have been no changes of Accountants during the two most recent fiscal years.
**ITEM 8A.       CONTROLS AND PROCEDURES**
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 reports are recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.  Within 90 days prior to the date of this report, our management carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 15d-14. Based upon the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective in connection with the filing of this Annual Report on Form 10-KSB for the year ended December 31, 2003.

There were no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation, including any significant deficiencies or material weaknesses of internal controls that would require corrective action.
**ITEM 9.       DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT.**
The name, age and position held by each of the directors and officers of the Company are as follows:
**Name**Age**Position Held
 
 
 
Sidney Chan
52
Chief Executive Officer, Chief Financial Officer and member of the Board of Directors
 
 
 
Stanley Cruitt
53
President and member of the Board of Directors
 
 
 
Dr. Jaroslav Tichy
62
Vice President, Technology
All directors have a term of office expiring at the next annual general meeting of the Company, unless re-elected or earlier vacated in accordance with the Bylaws of the Company.  All officers have a term of office lasting until their removal or replacement by the board of directors.

 

 -37- ***Sidney Chan - Chief Executive Officer and a member of the Board of Directors of the Company.*
Since April 4, 2000, Mr. Chan has been the Chief Executive Officer of the Company and the Secretary/Treasurer since April 30, 2001.  From December 14, 1999 to April 4, 2000, Mr. Chan was the President of the Company.  Since December 14, 1999, Mr. Chan has been a member of the Board of Directors of the Company.  Since 1986, Mr. Chan has been the President of Knight's Financial Limited, a company based in Vancouver, British Columbia.
***Stanley Cruitt - President and a member of the Board of Directors of the Company.*
Since April 4, 2000, Mr. Cruitt has been President of the Company.  Since December 1, 2000, Mr. Cruitt has been a member of the Board of Directors.  From 1995 through to March, 2000, Mr. Cruitt was Director of Marketing Services and a member of the management team for Novartis Animal Health (formerly Ciba) and since December 1999, President of Horizon Marketing and Research Inc.
***Dr. Jaroslav V. Tichy - Vice President, Technology*
Since December 1, 2000, Dr. Tichy has been Vice President, Technology of the Company.  From 1984 through 2000, Dr. Tichy was a Systems Design Specialist with Weir-Jones Engineering Consultants Ltd.  Since 1997, Dr. Tichy has been President and CEO of Silentronix Systems Inc.
**Involvement in Certain Legal Proceedings**
To the Company's knowledge, during the past five years, its officers and directors:  has not filed a petition under the federal bankruptcy laws or any state insolvency law, nor had a receiver, fiscal agent or similar officer appointed by a court for the business or present of such a person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer within two years before the time of such filing; were not convicted in a criminal proceeding or named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); were not the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting the following activities: (i) acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, associated person of any of the foregoing, or as an investment advisor, underwriter, broker or dealer in securities, or as an affiliated person, director of any investment company, or engaging in or continuing any conduct or practice in connection with such activity; (ii) engaging in any type of business practice; (iii) engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of federal or state securities laws or federal commodity laws;  were not the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any federal or state authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described above under this Item, or to be associated with persons engaged in any such activity;  were not found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission to have violated any federal or state securities law and the judgment in 

 

 -38- 
subsequently reversed, suspended or vacate; and were not found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated. 
**Compliance with Section 16(a) of the Exchange Act.**
Based solely upon a review of Forms 3, 4 and 5 furnished to the Company during the fiscal year 2003, no officer and director failed to file their Form 3, 4 and 5 on a timely basis.
**Audit Committee and Charter**
The Company has an audit committee and audit committee charter.  The Company's audit committee is comprised of all of its officers and directors.  None of directors are deemed independent.  All directors also hold positions as officers of the Company.  A copy of the Company's audit committee charter is filed as an exhibit to this report.  The Company's audit committee is responsible for: (1) selection and oversight of its independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; (3) establishing procedures for the confidential, anonymous submission by company employees of concerns regarding accounting and auditing matters; (4) engaging outside advisors; and, (5) funding for the outside auditory and any outside advisors engagement by the audit committee. A copy of the Company's audit committee charter is filed as an exhibit to this report. 
**Audit Committee Financial Expert**
The Company has no financial expert.  It believes the cost related to retaining a financial expert at this time is prohibitive.  Further, because of the Company's limited operations, management believes the services of a financial expert are not warranted.
**Code of Ethics**
The Company has adopted a corporate code of ethics.  A copy of the code of ethics is filed as an exhibit to this report.  The Company believes its code of ethics is reasonably designed to deter wrongdoing and promote honest and ethical conduct; provide full, fair, accurate, timely and understandable disclosure in public reports; comply with applicable laws; ensure prompt internal reporting of code violations; and provide accountability for adherence to the code.
**Disclosure Committee and Charter**
The Company has a disclosure committee and disclosure committee charter.  The Company's disclosure committee is comprised of all of its officers and directors.  The purpose of the committee is to provide assistance to the Chief Executive Officer and the Chief Financial Officer in fulfilling their responsibilities regarding the identification and disclosure of material information about the Company and the accuracy, completeness and timeliness of the Company's financial reports.  A copy of the Company's disclosure committee charter is filed with this report.  

 

 -39- **ITEM 10.       EXECUTIVE COMPENSATION.**
The following table sets forth information with respect to compensation paid by the Company to officers and directors during the three most recent fiscal years.
**Summary Compensation Table**

 
 ** **Long Term Compensation** ** **Annual Compensation**Awards**Payouts**(a)**(b)**(c)**(d)**(e)**(f)**(g)**(h)**(i)** ** ** ** ** ** ** ** ** ** ** ** ** **Other **Restricted **Securities ** **All Other** ** ** ** **Annual **Stock **Underlying **LTIP**Compen- **Name and Principal** ** **Bonus**Compen-**Award(s)**Options / **Payouts**sation**Position**Year**Salary ($)**($)**sation  ($)1**($)**SARs (#)**($)**($)** 
 
 
 
 
 
 
 
 
Sidney Chan2
2003
144,000
0
9,600
0
0
0
0
 CEO &
2002
144,000
0
9,600
0
0
0
0
 Director
2001
144,000
0
9,600
0
0
0
0
 
 
 
 
 
 
 
 
 
Stanley Cruitt3
2003
156,000
0
9,600
0
0
0
0
 President &
2002
156,600
0
9,600
0
0
0
0
 Director
2001
156,600
0
0
0
0
0
0
 
 
 
 
 
 
 
 
 
Robert Frattaroli.4
2003
72,500
0
0
0
0
0
0
Executive Vice 
2002
120,000
 
0
0
0
0
0
President (resigned 
2001
70,000
 
0
0
0
0
0
August 2003)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dr. Jaroslav V. 
2003
60,000
0
0
0
0
0
0
Tichy,5 Vice 
2002
35,000
0
0
0
0
0
0
President - 
2001
30,000
0
0
0
0
0
0
Technology
 
 
 
 
 
 
 
 
[1]  
Automobile allowance
[2] 
At December 31, 2003, salaries and other annual compensation for fiscal 2003, 2002 and 2001 totaling $176,100 and the $150,000 bonus for fiscal 2000 remain unpaid and are included in accounts payable and accrued liabilities.
[3] 
At December 31, 2003, salaries and other annual compensation for fiscal 2003, 2002 and 2001 totaling $406,650 remain unpaid and are included in accounts payable and accrued liabilities.
[4] 
At December 31, 2003, salaries and other annual compensation for fiscal 2003, 2002 and 2001 totaling $171,500 remain unpaid and are included in accounts payable and accrued liabilities.  Mr. Frattaroli resigned as an officer of the Company in August, 2003.
[5]
At December 31, 2003, salaries and other annual compensation for fiscal 2003 totaling $47,500 remain unpaid and are included in accounts payable and accrued liabilities.
 

 -40- 
The Company has irrevocably committed to grant 2,000,000 stock options to Sidney Chan, Chief Executive Officer and a Director of the issue, 4,000,000 stock options to Stanley Cruitt, President and a Director of the issuer and 1,000,000 options to Robert Frattaroli, Executive Vice President of the issuer.  The exercise price of the options will be $0.25 per share and they will be exercisable for a period of five years. 

The Company does not have a non-qualified incentive stock option plan.  In the future the Company intends to adopt such a plan to satisfy its contractual commitments to Messrs. Chan, Cruitt and Frattaroli. 

The Company does not have any long-term incentive plans and accordingly no grants were made in the 2002 fiscal year to employees.

The Company has entered into three year contracts with its named executive officers providing the following annual compensation.

Sidney Chan 
$
 144,000
Stanley Cruitt
$
 156,600
Robert Frattaroli
$
 120,000
Dr. Jarek Tichy
$
  60,000

The contracts may be terminated by the Company at any time, effective thirty days after delivery of notice, without any further compensation.

The terms of Mr. Chan's contract also provides for a commission of 1.0% of net sales during the term of the agreement as well as a bonus payment on commencement of commercial production of the Pet Reminder.  As indicated above, Mr. Chan will also be entitled to 2,000,000 options with a five year term exercisable at $0.25.  In addition, if more than 50% of the Company's stock or assets are sold, Mr. Chan will be compensated for entering into a non-compete agreement based on the selling price of the Company or its assets as follows:
**Sales Price**
 **From
 **To
 **Participation
 
$
0
 
$
  24,999,999
 
2% plus
 
$
25,000,000****************************************************************************************************************************************************************************************************************************************